Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Maurer, Gerald (55606327600)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Criteria for surveys: From the European Association of Cardiovascular Imaging Scientific Initiatives Committee
    (2019)
    Haugaa, Kristina H. (24733615600)
    ;
    Marsan, Nina Ajmone (23035780700)
    ;
    Cameli, Matteo (36906722500)
    ;
    D'Andrea, Antonello (55612687400)
    ;
    Dweck, Marc R. (12783691400)
    ;
    Carvalho, Ricardo Fontes (57210811139)
    ;
    Holte, Espen (23024605700)
    ;
    Manka, Robert (8839069800)
    ;
    Michalski, Blazej (14527627100)
    ;
    Podlesnikar, Tomaz (57188636569)
    ;
    Popescu, Bogdan A. (37005664700)
    ;
    Schulz-Menger, Jeanette (6701382131)
    ;
    Sitges, Marta (7006509888)
    ;
    Stankovic, Ivan (57197589922)
    ;
    Maurer, Gerald (55606327600)
    ;
    Edvardsen, Thor (6603263370)
    The European Association of Cardiovascular Imaging (EACVI) is committed to maintaining the highest standards of professional excellence in all aspects of cardiovascular imaging. The mission of the EACVI is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging with a particular focus on education, training, scientific initiatives, and research. The EACVI established the Scientific Initiatives Committee (SIC) in December 2018. This committee has responsibility for surveys among imagers, patients' surveys and surveys including data from clinical practice. The current document describes the aims of the EACVI SIC and the creation of the international EACVI survey network. This document summarizes the EACVI's standards for the survey questions and standards for writing the papers with the results of the surveys. These are in accordance with previous recommendations and were approved by the EACVI SIC and the EACVI Board in 2019. © 2019 Published on behalf of the European Society of Cardiology. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    EACVI survey on hypertrophic cardiomyopathy
    (2022)
    Podlesnikar, Tomaz (57188636569)
    ;
    Cardim, Nuno (7004229183)
    ;
    Ajmone Marsan, Nina (23035780700)
    ;
    D'Andrea, Antonello (55612687400)
    ;
    Cameli, Matteo (36906722500)
    ;
    Popescu, Bogdan A (37005664700)
    ;
    Schulz-Menger, Jeanette (6701382131)
    ;
    Stankovic, Ivan (57197589922)
    ;
    Toplisek, Janez (56085208200)
    ;
    Maurer, Gerald (55606327600)
    ;
    Haugaa, Kristina H (24733615600)
    ;
    Dweck, Marc R (12783691400)
    Aims: The European Association of Cardiovascular Imaging (EACVI) Scientific Initiatives Committee performed a global survey to evaluate current practice for the assessment and management of patients with hypertrophic cardiomyopathy (HCM). Methods and results: A total of 213 centres from 38 different countries (87% European) responded to the survey. One hundred twenty-one (57%) centres followed HCM patients in a general cardiology outpatient clinic and 85 (40%) centres in a specialized HCM/cardiomyopathy clinic. While echocardiography was the primary imaging modality, cardiovascular magnetic resonance (CMR) has become an important complementary tool. Cardiac anatomy, left ventricular (LV) systolic, and diastolic function were assessed according to current European guidelines and recommendations. To evaluate LV obstruction, 49% of the centres performed bedside provocation manoeuvres in every patient and 55% of the centres used exercise stress echocardiography. The majority of centres used the 5-year risk assessment of sudden cardiac death (SCD) calculated with the HCM Risk-SCD score. However, 34% of the centres also used extensive non-infarct late gadolinium enhancement on CMR and 27% the presence of LV apical aneurysm to help select patients for primary prevention implantable cardioverter-defibrillator therapy. Ninety-nine percent of the responding centres performed regular imaging follow-up of HCM patients. Conclusion: Most centres followed European guidelines and recommendations for the diagnosis and management of patients with HCM. The importance of bedside provocation manoeuvres and exercise stress echocardiography to diagnose LV outflow obstruction requires emphasis. Additional risk markers for SCD are used in many centres and might indicate the need for an update of current European recommendations. © 2021 Published on behalf of the European Society of Cardiology. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback